Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience
The aim of this study was to determine the frequency of hypophosphatemia in female patients with iron deficiency anemia (IDA) treated parenterally with ferric carboxymaltose (FCM). Thirty-two female patients examined for IDA at the Hematology and Oncology Department of one General Hospital were i...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sestre Milosrdnice University hospital, Institute of Clinical Medical Research
2024-01-01
|
| Series: | Acta Clinica Croatica |
| Subjects: | |
| Online Access: | https://hrcak.srce.hr/file/481686 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850100091818344448 |
|---|---|
| author | Nikolina Brkić Ivana Vučinić Ljubičić Hrvoje Holik Božena Coha |
| author_facet | Nikolina Brkić Ivana Vučinić Ljubičić Hrvoje Holik Božena Coha |
| author_sort | Nikolina Brkić |
| collection | DOAJ |
| description | The aim of this study was to determine the frequency of hypophosphatemia in
female patients with iron deficiency anemia (IDA) treated parenterally with ferric carboxymaltose
(FCM). Thirty-two female patients examined for IDA at the Hematology and Oncology Department
of one General Hospital were included in the study. The inclusion criteria were hemoglobin <110 g/L,
transferrin saturation <50%, ferritin <30 ng/mL, and ineffective oral iron therapy. The hemoglobin
values were significantly increased 6 weeks after therapy in comparison with initial values. The onset
of the asymptomatic hypophosphatemia was observed in 17 of 32 patients two weeks after the FCM
therapy. Only one of 32 patients had severe asymptomatic hypophosphatemia (serum phosphate <0.3
mmol/L). Prolonged hypophosphatemia (6 weeks after FCM therapy) was observed in five of 32
patients, of which only one patient had initial hypophosphatemia. The difference between the phosphate
values measured two weeks after the FCM therapy and the phosphate values at the first and last
follow-up was statistically significant. Serum phosphate values should be routinely measured before
and after parenteral FCM therapy. |
| format | Article |
| id | doaj-art-6eb41588abf14060b49a53d33e2b88e2 |
| institution | DOAJ |
| issn | 0353-9466 1333-9451 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Sestre Milosrdnice University hospital, Institute of Clinical Medical Research |
| record_format | Article |
| series | Acta Clinica Croatica |
| spelling | doaj-art-6eb41588abf14060b49a53d33e2b88e22025-08-20T02:40:21ZengSestre Milosrdnice University hospital, Institute of Clinical Medical ResearchActa Clinica Croatica0353-94661333-94512024-01-0163.3-447548110.20471/acc.2024.63.03-04.03Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center ExperienceNikolina Brkić0Ivana Vučinić Ljubičić1Hrvoje Holik2Božena Coha3Department of Transfusion medicine, General Hospital Vinkovci, Vinkovci, Croatia; Faculty of Medicine, University of Osijek, Osijek, CroatiaHematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, CroatiaHematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, CroatiaHematology and Oncology Department, “Dr. Josip Benčević” General Hospital, Slavonski Brod, CroatiaThe aim of this study was to determine the frequency of hypophosphatemia in female patients with iron deficiency anemia (IDA) treated parenterally with ferric carboxymaltose (FCM). Thirty-two female patients examined for IDA at the Hematology and Oncology Department of one General Hospital were included in the study. The inclusion criteria were hemoglobin <110 g/L, transferrin saturation <50%, ferritin <30 ng/mL, and ineffective oral iron therapy. The hemoglobin values were significantly increased 6 weeks after therapy in comparison with initial values. The onset of the asymptomatic hypophosphatemia was observed in 17 of 32 patients two weeks after the FCM therapy. Only one of 32 patients had severe asymptomatic hypophosphatemia (serum phosphate <0.3 mmol/L). Prolonged hypophosphatemia (6 weeks after FCM therapy) was observed in five of 32 patients, of which only one patient had initial hypophosphatemia. The difference between the phosphate values measured two weeks after the FCM therapy and the phosphate values at the first and last follow-up was statistically significant. Serum phosphate values should be routinely measured before and after parenteral FCM therapy.https://hrcak.srce.hr/file/481686Ferric carboxymaltoseHypophosphatemiaIron deficiency anemia |
| spellingShingle | Nikolina Brkić Ivana Vučinić Ljubičić Hrvoje Holik Božena Coha Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience Acta Clinica Croatica Ferric carboxymaltose Hypophosphatemia Iron deficiency anemia |
| title | Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience |
| title_full | Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience |
| title_fullStr | Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience |
| title_full_unstemmed | Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience |
| title_short | Transient Hypophosphatemia as Possible Adverse Outcome after Iron Deficiency Anemia Treatment with Ferric Carboxymaltose – Single Center Experience |
| title_sort | transient hypophosphatemia as possible adverse outcome after iron deficiency anemia treatment with ferric carboxymaltose single center experience |
| topic | Ferric carboxymaltose Hypophosphatemia Iron deficiency anemia |
| url | https://hrcak.srce.hr/file/481686 |
| work_keys_str_mv | AT nikolinabrkic transienthypophosphatemiaaspossibleadverseoutcomeafterirondeficiencyanemiatreatmentwithferriccarboxymaltosesinglecenterexperience AT ivanavucinicljubicic transienthypophosphatemiaaspossibleadverseoutcomeafterirondeficiencyanemiatreatmentwithferriccarboxymaltosesinglecenterexperience AT hrvojeholik transienthypophosphatemiaaspossibleadverseoutcomeafterirondeficiencyanemiatreatmentwithferriccarboxymaltosesinglecenterexperience AT bozenacoha transienthypophosphatemiaaspossibleadverseoutcomeafterirondeficiencyanemiatreatmentwithferriccarboxymaltosesinglecenterexperience |